Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds

By M. Bonkowski, D. Sinclair. Nature reviews. Molecular cell biology, 2016

748 citations recorded by the source corpus.

The sirtuins (SIRT1–7) are a family of nicotinamide adenine dinucleotide (NAD+)-dependent deacylases with remarkable abilities to prevent diseases and even reverse aspects of ageing. Mice engineered to express additional copies of SIRT1 or SIRT6, or treated with sirtuin-activating compounds (STACs) such as resveratrol and SRT2104 or with NAD+ precursors, have improved organ function, physical endurance, disease resistance and longevity. Trials in non-human primates and in humans have indicated that STACs may be safe and effective in treating inflammatory and metabolic disorders, among others. These advances have demonstrated that it is possible to rationally design molecules that can alleviate multiple diseases and possibly extend lifespan in humans.

Subfields: Aging, Geriatrics and Gerontology, Physiology

View Paper: https://www.semanticscholar.org/paper/bb652bfe1cdbc977bb187ca9ee55f2780d2875a0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Tie
2. Dahai Hu
3. Yunshu Yang
4. Jinxin Zhang
5. Yang Liu
6. Y. Chao
7. Yanhui Jia
8. Yunwei Wang

Citations in the corpus

• Therapeutic potential of NAD-boosting molecules: the in vivo evidence (2018, neutral): “Whether or not the ability of CD38 to raise NAD+ levels in tissues is due to intraor extracellular activity remains to be determined (Bonkowski and Sinclair, 2016; Gupte et al., 2017).”
• Regulation of SIRT1 and Its Roles in Inflammation (2022, background): “SIRT1 was the first SIRT to be discovered in mammals; it shares the highest homology with Sir2, and is the most extensivelystudied SIRT protein that plays a role in promoting longevity (2).”